BioCryst Pharmaceuticals BCRX Common stock, shares authorized (in shares)
Common stock, shares authorized (in shares) at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's common stock, shares authorized (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's common stock, shares authorized (in shares)?
- BioCryst Pharmaceuticals (BCRX) reported common stock, shares authorized (in shares) of $450M in Q1 2026.
- How has BioCryst Pharmaceuticals's common stock, shares authorized (in shares) changed year-over-year?
- BioCryst Pharmaceuticals's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $450M to $450M.
- What is the long-term trend for BioCryst Pharmaceuticals's common stock, shares authorized (in shares)?
- Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $450M to $450M.